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Stress-induced phosphoprotein 1 (STIP1), a cocha-
perone that organizes other chaperones, heat shock
proteins (HSPs), was recently shown to be secreted
by human ovarian cancer cells. In neuronal tissues,
binding to prion protein was required for STIP1
to activate the ERK (extracellular-regulated MAP
kinase) signaling pathways. However, we report
that STIP1 binding to a bone morphogenetic protein
(BMP) receptor, ALK2 (activin A receptor, type II-like
kinase 2), was necessary and sufficient to stimulate
proliferation of ovarian cancer cells. The binding
of STIP1 to ALK2 activated the SMAD signaling
pathway, leading to transcriptional activation of ID3
(inhibitor of DNA binding 3), promoting cell prolifera-
tion. In conclusion, ovarian-cancer-tissue-secreted
STIP1 stimulates cancer cell proliferation by binding
to ALK2 and activating the SMAD-ID3 signaling path-
ways. Although animal studies are needed to confirm
these mechanisms in vivo, our results may pave the
way for developing novel therapeutic strategies for
ovarian cancer.
INTRODUCTION
Ovarian cancer is the gynecologic tumor with the highest
mortality because most patients with ovarian cancer are diag-
nosed in advanced stages. Several genes, including BRCA1/2
(breast cancer 1/2, early onset), KRAS, BRAF, and TP53, have
been associated with tumorigenesis in ovarian cancer, but their
molecular mechanisms remain unclear (Bast et al., 2009).
Currently, CA125 is the only tumor marker for monitoring the
disease progression of ovarian cancer, but it does not cover all
ovarian cancers (Karam and Karlan, 2010). Better understanding
of the molecular mechanisms of ovarian cancer may help us
develop novel therapeutic strategies.Stress-induced phosphoprotein 1 (STIP1, STI 1, gene ID
10963), also referred as heat shock protein (HSP) 70/90 orga-
nizing protein (HOP), is a 62.6 kDa protein that contains nine tet-
ratricopeptide repeat (TPR) motifs and one nuclear localization
signal (NLS) (Longshaw et al., 2004). The TPR domains of
STIP1 are involved in holding HSP70 and HSP90 together in
the HSP90 chaperone machinery (Odunuga et al., 2004). This
formation of protein complexes participates in several cellular
processes including transcription, protein folding, protein trans-
location, viral replication, signal transduction, and cell division
(Arbeitman and Hogness, 2000; Bharadwaj et al., 1999; Hu
et al., 2002; Johnson et al., 1998; Martins et al., 1997; Zanata
et al., 2002). The NLS sequence allows STIP1 transport from
cytoplasm to the nucleus under the control of cell-cycle kinases
(Longshaw et al., 2004).
STIP1 lacks a transmembrane domain or signal peptide; thus,
it was previously considered to be a cytoplasmic protein (La¨ssle
et al., 1997). However, recent studies indicate that it can be
translocated to the cell surface or secreted out of the cell
(Eustace and Jay, 2004; Wang et al., 2010). Extracellular STIP1
binds to prion proteins on cell surfaces and induces neuropro-
tective signals that rescue the cell from apoptosis (Roffe´ et al.,
2010; Zanata et al., 2002). In glioblastoma cells, extracellular
STIP1 was shown to trigger endogenous mitogen-activated
protein kinase 1/2 (ERK1/ERK2), protein kinase A (PKA), and
phosphatidylinositol 3-kinase (PI3K) signaling pathways,
promoting cell proliferation (Caetano et al., 2008; Erlich et al.,
2007; Lopes et al., 2005). Once the interaction between STIP1
and prion protein takes place at the cell surface, the protein is
endocytosed, and transient ERK1/ERK2 activation occurs
(Caetano et al., 2008).
Bone morphogenetic protein (BMP) pathways are involved in
various cell functions, including cell proliferation and migration
(Kitisin et al., 2007). These pathways are also important for
embryonic development and tumorigenesis (Blanco Calvo
et al., 2009; Waite and Eng, 2003). Ligands of the BMP family
bind to two distinct membrane receptors, known as type I and
type II receptors, which contain serine/threonine kinase domains
in their intracellular portions. Upon binding of this ligand, theseCell Reports 2, 283–293, August 30, 2012 ª2012 The Authors 283
Figure 1. Secreted STIP1 Activated ID3 at the Transcriptional Level
(A) After being cultured in serum-free medium for 24 hr, MDAH2774 and SKOV3 cells were treated with 0.4 mM of rhSTIP1 for 24 hr. The resultant RNAs were
analyzed with Affymetrix U133A microarrays. The data shown were obtained from two independent experiments in each cell line.
(B) Activation of ID3 by treatment with STIP1 was confirmed by real-time QPCR at different time points. The data (mean ± SE) shown were obtained from three
independent experiments, in which GAPDH was used for normalization purposes. Asterisks denote statistical significance (p < 0.05, paired Student’s t test).
(C) After MDAH2774 and SKOV3 cells were treated with 0.4 mMof rhSTIP1 for 1 hr, increased ID3 protein levels were detected by western blot analyses. The actin
level was used to normalize the input protein.
(D) ID3 promoter luciferase assays were performed in embryonic kidney 293 and SKOV3 cells. Results shown are the mean ± SE of three independent exper-
iments. Asterisks denote statistical significance (p < 0.05, paired Student’s t test).
See also Table S1 and Figure S1.two receptors form a hetero-complex where the type II receptor
phosphorylates the type I receptor and activates receptor-regu-
lated SMADs (R-SMADs), SMAD1/SMAD5 (Hardwick et al.,
2008). Once phosphorylated, SMAD1/SMAD5 form a complex
with a common SMAD (co-SMAD), SMAD4 (Heldin et al., 1997).
Then, the R-SMADs and co-SMAD complexes are translocated
into the nucleus to regulate the transcription of target genes,
including IDs (inhibitor of DNAbinding) (Miyazono andMiyazawa,
2002). ID proteins compete with the retinoblastoma protein (Rb)
to interact with E2F.When E2F is released from Rb, the cell cycle
enters the S phase from the G0/G1 phase (Lasorella et al., 2000).
Ovarian cancers produce higher levels of STIP1 than benign
tumors do. Because STIP1 is secreted into the blood, the serum
STIP1 concentrations in patients with ovarian cancer were signif-
icantly higher than those in age-matched controls (Wang et al.,
2010). Supporting these findings, Kim and associates found
that serum STIP1 autoantibodies were also increased in patients
with ovarian cancer (Kim et al., 2010). Treatment of cells with re-
combinant human STIP1 (rhSTIP1) stimulates ERK1/ERK2 phos-
phorylation, activates DNA synthesis (Arruda-Carvalho et al.,284 Cell Reports 2, 283–293, August 30, 2012 ª2012 The Authors2007; Erlich et al., 2007), and enhances cell proliferation (Wang
et al., 2010). These results suggest that STIP1 in cancer cells
acts as a cytokine, with the ability to stimulate cell proliferation.
In this study our microarray results revealed that ID proteins
were upregulated by treatment of ovarian cancer cells with
rhSTIP1. Interestingly, ERK1/ERK2 was not involved in these
STIP1-activated ID pathways. In an attempt to dissect how
STIP1 promotes the proliferation of ovarian cancer cells through
an ERK-independent pathway, we found that STIP1 binds to
a BMP receptor, activin A receptor, type II-like kinase 2 (ALK2)
(the updated gene symbol as ACVR1, gene ID 90), and activates
ID proteins via the SMAD signaling pathway.
RESULTS
STIP1 Activated Expression of ID1, ID3, and ID4 in
Ovarian Cancer Cells
From microarray analysis of gene expression, we found that five
genes were upregulated by treatment with rhSTIP1 for 24 hr in
MDAH2774 and SKOV3 (Figures 1A and S1; Table S1). ID3 gene
Figure 2. Secreted STIP1 Activated ID3 through SMAD Proteins
(A) Knockdown of endogenous SMAD1 and SMAD5 by siRNA decreased the
stimulation of ID3 protein levels by treatment with 0.4 mM of rhSTIP1.
(B) Suppression of endogenous STIP1 by siRNA did not affect ID3 stimulation
by rhSTIP1.
(C) STIP1-induced binding of SMADs to two ID3 promoter regions was
assayed with ChIP assays with anti-SMAD1/SMAD5 antibody. Two putative
SMAD1/SMAD5-responsive elements (BREs) in ID3 promoter region are
depicted in the upper panel. The PCR products were separated by 5%
nondenature acrylamide gel.
(D) Two reported SMAD binding sites in ID3 promoter are at the 1 kb region
(shown in black bar) and the 3 kb region (shown in gray bar). Three
independent ChIP experiments were quantified by real-time QPCR, and
results shown are mean ± SE.
See also Figure S2.that promotes cell proliferation was markedly activated by
treatment with rhSTIP1 in ovarian cancer cell lines (Figure 1A).
STIP1-activated expression of ID3 was further validated by real-
time quantitative PCR (QPCR) at different time points (Figure 1B).
Also, the amount of ID3 protein was increased by treatment with
rhSTIP1 in ovarian cancer cells (Figure 1C). Results of the ID3
promoter reporter assays indicated that STIP1 stimulated the
full-length activity from 1.9- to 2.3-fold. The reporter activities
were decreased in the truncated promoters: down from 1.3- to
2.0-fold for the 4,432 to 2,281 reporter, 0.7- to 1.2-fold for
the2,281 to +75 reporter, and no activation for the982 to +75
reporter (Figure 1D). These results suggested that the STIP1
response element is located in the 4,432 to 2,281 region of
the ID3 promoter, where several SMAD binding sites are located.
The SMAD Signaling Pathways, but Not ERK Pathways,
Were Involved in the Activation of ID Proteins by STIP1
Our previous results indicated that STIP1 activates ERKs (Wang
et al., 2010), so we used the ERK-specific inhibitor, PD98059, totest whether the ERK pathway was involved in the activation of
ID proteins. Surprisingly, treatment with PD98059 did not signif-
icantly inhibit the effective activation of ID3 mRNA by rhSTIP1
treatment (Figure S2A), and the stimulation of pSMAD1/pSMAD5
by rhSTIP1 was not significantly suppressed by PD98059, either
(Figure S2B). Because SMAD proteins were shown to be
involved in the activation of ID proteins in ovarian cancer (Herrera
et al., 2009; Shepherd et al., 2008), we used RNAi to examine the
roles of SMAD proteins in the activation of ID3 protein by STIP1.
Knocking down SMAD1 and SMAD5 significantly suppressed
the activation of ID proteins by rhSTIP1 (Figure 2A). We also
checked the role of endogenous STIP1 in ID3 stimulation with
small interfering RNA (siRNA) technology. After expression of
endogenous STIP1 was suppressed, we still observed the stim-
ulation of ID3 by rhSTIP1 (Figure 2B).
Because there are two BMP-responsive elements (BREs) in
the ID3 gene (Shepherd et al., 2008), we used anti-SMAD1/
SMAD5 antibodies in chromatin immunoprecipitation (ChIP)
assays to test whether STIP1 activated the binding of SMAD
proteins to the enhancer region of the ID3 gene. Real-time
QPCR results confirmed that treatment of cancer cells with
rhSTIP1 increased the binding of SMAD proteins to the 1 and
the 3 kb enhancer regions of ID3 gene (Figures 2C and 2D).
Taken together, these results indicate that STIP1 activates the
expression of ID3 through the SMAD proteins.
STIP1 Induced Phosphorylation of Endogenous
SMAD1/SMAD5 in Ovarian Cancer Cells
Treatment of human ovarian cancer MDAH2774 cells with
rhSTIP1 induced phosphorylation of SMAD1/SMAD5 in time-
dependent (Figure 3A) and dose-dependent (Figure 3B) fash-
ions. The induction of SMAD phosphorylation by rhSTIP1 was
also detected in six other human ovarian cancers (Figure 3C).
These results indicated that STIP1 activates the canonical
SMAD1/SMAD5 pathway in ovarian cancer cells.
Binding to ALK2 Receptors Was Required for
STIP1-Induced Phosphorylation of SMAD1/SMAD5
To test whether the prion protein was required for the phosphor-
ylation of SMAD proteins by STIP1, we knocked down the prion
protein with siRNA. The knockdown of prion did not suppress the
STIP1-induced phosphorylation of SMAD1/SMAD5 (Figure S3).
On the other hand, 5 nM of the BMP receptor and serine/threo-
nine kinase inhibitor, LDN193189, effectively blocked the STIP1-
induced phosphorylation of SMADs (Figure 4A).
LDN193189 preferentially inhibits ALK2 and ALK3 (IC50 = 5
and 30 nM, respectively) but only weakly inhibits ALK4, ALK5,
and ALK7 (IC50 > 500 nM) (Yu et al., 2008). Knockdown of
ALK2 blocked STIP1-activated SMAD1/SMAD5 phosphoryla-
tion (Figure 4B), suggesting that the BMP receptor ALK2 is
required for STIP1 to activate ovarian cancer cells. Colocaliza-
tion of rhSTIP1 and ALK2 was also observed by confocal immu-
nofluorescent microscopy (Figure 4C). Because some colocal-
ized signals were found intracellularly after rhSTIP1 treatment
for 15 min, we tested whether endocytosis was important for
rhSTIP1-induced SMAD1/SMAD5 phosphorylation. As an inhib-
itor of dynamins, Dynasore blocks the formation of clathrin-
coated vesicles (Macia et al., 2006). Clathrin-dependentCell Reports 2, 283–293, August 30, 2012 ª2012 The Authors 285
Figure 3. Secreted STIP1 Activated Phosphorylation of Endogenous
SMAD1/SMAD5
(A) MDAH2774 cells were serum starved for 24 hr and then treated with 0.4 mM
of STIP1 for 0, 5, 10, 20, and 60 min. The phospho-SMAD1/SMAD5 intensities
were assayed by western blot analyses. The total amount of SMAD5 and actin
was used as the protein loading control.
(B) After serum starvation for 24 hr, MDAH2774 cells were treated with various
concentrations of rhSTIP1 for 20 min, and assayed for the activation of
phospho-SMAD1/SMAD5 (upper panel). Summary of dose-responsive
activation of phospho-SMAD1/SMAD5 by treatment with rhSTIP1 for 20 min
(lower panel). Results shown are the mean ± SE from three independent
experiments.
(C) Activation of phospho-SMAD1/SMAD5 by treatment with 0.4 mM of
rhSTIP1 for 20 min in six other ovarian cancer cell lines.internalization was also required for BMP-SMAD signal trans-
duction (Hartung et al., 2006; Sieber et al., 2009). The interaction
between rhSTIP1 and clathrin was also observed in confocal
immunofluorescent microscopy (Figure 4C). The interaction of
rhSTIP1 and ALK2 was disrupted (Figure 4C), and the induction
of phospho-SMAD1/SMAD5 by rhSTIP1 was repressed by286 Cell Reports 2, 283–293, August 30, 2012 ª2012 The Authorstreatment of Dynasore (Figure 4D), suggesting that clathrin-
dependent endocytosis was required for the STIP1-activated
ALK2-SMAD signaling pathway. Physical interactions between
rhSTIP1 and ALK2 were further confirmed by immunoprecipita-
tion (Figure 4E) and pull-down experiments (Figure S3B) followed
by western blot analyses (Figures 4E and S3B). To verify that
phospho-SMADs were specifically induced by the interaction
between STIP1 and ALK2, we used a STIP1-neutralizing anti-
body and ALK2 fusion protein to block the rhSTIP1 activation
of the SMAD pathway. At the molarity ratio between anti-STIP1
antibody and rhSTIP1 at 2:1, rhSTIP1-induced SMAD1/SMAD5
phosphorylation decreased, and such phosphorylation was
completely blocked at the ratio of 4:1 (Figure 4F). Similarly, the
ALK2-Fc fusion protein at 8-fold molar ratio (ALK2-Fc fusion
protein, rhSTIP1 at 8:1) suppressed the rhSTIP1-activated
SMAD1/SMAD5 phosphorylation, and the ALK2-Fc fusion
protein at a molar ratio of 16:1 completely blocked SMAD1/
SMAD5 phosphorylation (Figure 4G). These results collectively
indicated that exogenous STIP1 activated the phosphorylation
of SMAD1/SMAD5 through its binding to ALK2 receptor, but
not through binding to prion protein as previously reported by
Zanata et al. (2002).
STIP1 Induced Cell Proliferation through the
ALK2-SMAD Pathway
BrdU is an analog of thymidine that can replace thymidine during
DNA replication, and Ki67 is a nuclear protein that is associated
with cell proliferation. We used BrdU incorporation assay and
immunocytochemistry for endogenous Ki67 as indicators for
cell proliferation (Wang et al., 2010). Treatment with rhSTIP1
increased the BrdU incorporation rate and Ki67 staining of
ovarian cancer cells, and these activations were completely
blocked by treatment with an ALK2/ALK3 inhibitor LDN193189
(Figures 5A and 5B), a STIP1-neutralizing antibody (Figures 5C
and 5D), or an ALK2 siRNA (Figures 5E and 5F). Of note, inhibi-
tion of ERK activity by PD98059 strongly inhibited cell prolifera-
tion, but even in such inhibition, treatment with rhSTIP1 still
significantly stimulated BrdU incorporation (Figure 5A). These
results indicated that ERK pathways are very important for cell
proliferation, but the ALK2-SMAD might be more specific for
the rhSTIP1-stimulated cell proliferation. Furthermore, knock-
down of endogenous STIP1 alone did not inhibit cell proliferation
and neither did it affect the stimulation of cell proliferation by
treatment with exogenous rhSTIP1 (Figures 5E and 5F).
Serum STIP1 concentrations were previously shown to be
higher in patients with ovarian cancer than age-matched healthy
controls (Wang et al., 2010). To further confirm that ovarian
cancer tissues were the source of elevated serum STIP1, we
showed that serum levels of STIP1 in patients with ovarian
cancer were significantly decreased after surgery (p < 0.01)
(Figure 6A). Immunohistochemical analyses of human ovarian
cancer tissues also demonstrated that increased levels of
STIP1 were positively correlated with increased amounts of
phospho-SMAD1/SMAD5 proteins and ID3 (Figure 6B). Notably,
ALK2 staining was also shown in the nucleus, as previously
reported in the Human Protein Atlas (http://www.proteinatlas.
org/ENSG00000115170). Functions of such ALK2 are yet to be
clarified. Significantly positive correlations were found between
Figure 4. Secreted STIP1 Activated SMAD1/SMAD5 through Binding to a BMP Type I Receptor ALK2
(A) A BMP type I receptor inhibitor, LDN193189, inhibited the STIP1-activated phosphorylation of SMAD1/SMAD5. MDAH2774 cells were pretreated with various
concentrations of LDN193189 for 24 hr, before 0.4 mM of rhSTIP1 was added for 20 min.
(B) Knockdown of ALK2 with siRNA inhibited the rhSTIP1-activated phosphorylation of SMAD1/SMAD5.
(C) Intracellular colocalization of exogenous STIP1 (green) and endogenous ALK2 (red, left panel), clathrin (red, middle panel) or endogenous ALK2 in the
presence of Dynasore (red, right panel) shown by confocal microscopy. After ovarian cancer cells were treated with rhSTIP1 for 15 min, exogenous STIP1 was
detected with an antibody that recognized the V5 tag of rhSTIP1 (green), whereas ALK2 or clathrin was detected by an anti-ALK2 or anti-clathrin antibody (red).
(D) Endocytosis was essential for rhSTIP1-induced SMAD1/SMAD5 phosphorylation. Cells were pretreated with endocytosis inhibitor-Dynasore for 2 hr, then
treated with 0.4 mM of rhSTIP1 for 20 min.
(E) After proteins in the rhSTIP1-treated cells were crosslinked, the protein complex around ALK2 from 2,000 mg of protein lysate was immunoprecipitated with
specific anti-ALK2 (a-ALK2) antibody, and exogenous rhSTIP1 was identified by western blot analysis with an anti-His tag antibody. A total of 50 mg of identical
protein lysates was used as loading control and probed with anti-His and anti-STIP1 antibodies.
(F and G) STIP1-neutralizing antibody and ALK2-Fc inhibited the rhSTIP1-induced SMAD1/SMAD5 phosphorylation. rhSTIP1 was preincubated with antibody or
ALK2-Fc for 1 hr at 37C, then added to cells for 20 min. Western blots were performed with indicated antibodies.
See also Figure S3.
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Figure 5. STIP1-ALK2-SMAD Pathway
Promoted Cell Proliferation
BrdU incorporation assay and immunointensity
of Ki67 protein (brown) were used as an index for
cell proliferation. (A), (C), and (E) summarize the
results of BrdU incorporation assays, and (B), (D),
and (F) show representative pictures of Ki67
immunocytochemistry of MDAH2774 cancer cells
treated with ALK inhibitor, LDN 193189, ERK
inhibitor PD98059 (A and B), STIP1-neutralizing
antibody (C and D), ALK2 siRNA, and STIP1si
(E and F), respectively. Results shown are the
mean ± SE from three independent experiments.
Asterisks denote statistical significance (p < 0.05,
paired Student’s t test). The scale bars represent
20 mm.STIP1 and phospho-SMAD1/SMAD5 expression (p < 0.005;
Figure S4A), between ID3 and phospho-SMAD1/SMAD5
(p < 0.001), and between STIP1 and ID3 expression (p < 0.0001;
Figure S4C). Collectively, these results suggest that, after STIP1
is secreted from ovarian tumor tissues, it binds to the ALK2
receptor of itself (autocrine) and/or neighboring cells (paracrine)
and triggers SMAD1/SMAD5 to activate ID3 expression in vivo.
DISCUSSION
In this study, we demonstrated that, in an autocrine and/or para-
crine fashion, secreted STIP1 from human ovarian cancer cells
binds to a BMP receptor, ALK2, phosphorylates cytoplasmic
SMAD1/SMAD5, and activates ID3 gene expression, promoting
cell proliferation. Marked phosphorylation of SMAD1/SMAD5
was induced by STIP1 at 10 min, and this effect lasted up to
1 hr (Figure 3A). This pattern is similar to that of BMP7 and
BMP9, in which these two proteins stimulated phosphorylation
of endogenous SMAD1/SMAD5 within 15 min and reached the288 Cell Reports 2, 283–293, August 30, 2012 ª2012 The Authorsmaximum between 30 and 60 min (Her-
rera et al., 2009; Macı´as-Silva et al.,
1998). Although STIP1 was reported to
bind to prion protein to activate ERK,
PAK, PI3K, and mTOR pathways in cells
(Caetano et al., 2008; Erlich et al., 2007;
Roffe´ et al., 2010), our results showed
that the prion protein was not required
for the STIP1-activated SMAD1/SMAD5
pathway (Figure 4A). Our findings of
prion-independent cell stimulation by
STIP1 are consistent with a previous
report by Arruda-Carvalho et al. (2007).
As a receptor serine/threonine kinase,
ALK2 interacts with BMP ligands such
as BMP6, BMP7, and BMP9, and phos-
phorylates the downstream SMAD1/
SMAD5 (Ebisawa et al., 1999; Herrera
et al., 2009; Macı´as-Silva et al., 1998).
We found that STIP1 colocalized and
biochemically interacted with ALK2 and
that ALK2 was required for the STIP1-induced SMAD signaling pathway (Figure 4). These results
strongly suggest that STIP1 is also a ligand for the ALK2-
SMAD pathway, although the protein sequence of STIP1 is
very different from that of BMPs.
BMPs regulate a variety of cell functions including prolifera-
tion, differentiation, apoptosis, and migration through phosphor-
ylation of SMAD1/SMAD5 (Alarmo and Kallioniemi, 2010), which
is also crucial for tumorigenesis in many cancers including
ovarian cancer. BMP4 induces epithelial to mesenchymal transi-
tion (EMT) in primary human ovarian cancer cells (The´riault et al.,
2007) and also stimulates cell proliferation via upregulation
of proto-oncogene ID3 in ovarian cancer cells (Shepherd et al.,
2008). Upregulated BMP2 in ovarian cancer cells stimulates
the expression of ID1, SMAD6, and SNAIL (Le Page et al.,
2009). In an autocrine fashion, BMP9 promotes the cell prolifer-
ation of immortalized human ovarian surface epithelial cells and
cancer cell lines through the ALK2/SMAD1/SMAD4 pathway
(Herrera et al., 2009). Carcinoma-associated mesenchymal
stem cells (CA-MSCs) from ovarian cancer exhibit increased
expression of BMP2, BMP4, and BMP6, which are required
for the in vitro and in vivo MSC-promoted tumor growth
(McLean et al., 2011). These results indicate that BMP pathways
play an important role in tumor cell proliferation of ovarian
cancer. However, this study shows that STIP1 secreted from
ovarian cancer tissues, similar to BMPs, promotes tumor cell
proliferation through the ALK2-SMAD1/SMAD5 pathway
(Figures 4 and 5).
Endogenous STIP1 interacts with HSP90 and participates in
HSP90-regulated signaling pathways (Taipale et al., 2010). This
interaction was shown to inhibit dimerization of HSP90 N
terminal and its ATPase activity (Lee et al., 2012; Li et al.,
2011), by which STIP1 may cause arrest of the cell cycle as
geldanamycin and its derivative 17-allylaminogeldanamycin
(17-AAG) do (Niikura et al., 2006). Indeed, our results showed
that knockdown of endogenous STIP1 by siRNA slightly
increased cell proliferation (Figures 5E and 5F). Nevertheless,
the STIP1-knocked down cells still responded to the treatment
with rhSTIP1 and further increased cell proliferation (Figures 5E
and 5F). Based on these results, we propose that endogenous
(intracellular) STIP1 may slightly suppress the progress of
the cell cycle by an inhibitory interaction with HSP90, but
exogenous (secreted) STIP1 may bind to cell membrane recep-
tors, prion or ALK2, trigger downstream pathways, and promote
cell proliferation.
We previously reported that serum levels of STIP1 in patients
with ovarian cancer (137.4 ± 112.7 ng/ml, mean ± SD) were
significantly higher than those of age-matched healthy controls
(23.8 ± 15.1 ng/ml) (Wang et al., 2010). The highest serum
STIP1 concentration in peripheral blood of patients with ovarian
cancer was about 1,700 ng/ml (Figure 6A). The serum STIP1
concentrations in patients with ovarian cancer significantly
decreased after surgery (Figure 6A), supporting that the cancer
tissues were the origin of elevated STIP1. Of note, 1.6 nM (about
100 ng/ml) of STIP1 activated greater than 2-fold of SMAD1/
SMAD5 phosphorylation (Figure 3B). Therefore, patients with
ovarian cancer likely had increased activation of ALK2-SMAD-
ID3 pathway from high-serum STIP1 levels. Indeed, the immuno-
histochemical results in ovarian cancer tissues (Figure 6B)
support this notion.
Our discovery that STIP1, in an autocrine or paracrine fashion,
promotes ovarian cancer cell proliferation through the ALK2-
SMAD1/SMAD5 signaling pathways may be used as proof for
principle for various therapeutic strategies. For example, STIP1
in circulation, more importantly those around the cancer tissues,
may be neutralized by specific antibodies (Figures 5C and 5D).
ALK2 may be inhibited by competitive inhibition with ALK2-Fc
fusion proteins (Figure 4G) or by a specific inhibitor (Figures 5A
and 5B). Furthermore, the siRNA technology may be applied to
all players of the signaling pathway, from STIP1 to ALK2 (Figures
5E and 5F) to SMADs (Figure 2).
In conclusion, ovarian cancer tissues secrete STIP1 into the
local environment and eventually into blood circulation. In an
autocrine or paracrine fashion, secreted STIP1 stimulates cancer
cell proliferation by binding to a BMP receptor, ALK2, and
activating the SMAD-ID3 signaling pathways. These results
may be useful for developing further therapeutic strategies for
ovarian cancer.EXPERIMENTAL PROCEDURES
Subjects
After informed consent was obtained from each patient, serum was collected
from Taiwanese patients with ovarian cancer before surgery and during the
postsurgery follow-up. All of the diagnoses of ovarian cancer were confirmed
by pathologists at Chang Gung Memorial Hospital (CGMH). This study
was approved by the Institutional Review Board of CGMH (IRB #94-975B,
#98-1982B, #98-1995A3).
Culture and Treatment of Cell Lines
Human ovarian cancer cell lines (SKOV3, TOV-21G, TOV 112D, OV-90,
MDAH2774) and human embryonic kidney epithelial 293 cells were obtained
from the American Type Culture Collection (Manassas, VA, USA). The ovarian
cancer cell lines BR (Wang et al., 1998) and BG1 (Geisinger et al., 1989) have
been previously described. All cells were cultured in DMEM/F12with 10% fetal
bovine serum and appropriate amounts of penicillin and streptomycin. Proto-
cols for rhSTIP1 purification and treatment have been previously reported
(Wang et al., 2010). rhSTIP1 was fused with two tags, 63 histidine and V5,
and thus, it could be purified or detected with nickel agarose, anti-his, or
anti-V5 antibodies. For the use of specific inhibitors, cells were pretreated
with 10 mM of PD98059 (ERK inhibitor; Calbiochem, Merck, Germany) for
1 hr, 80 mM of Dynasore (endocytosis inhibitor; Sigma-Aldrich, St. Louis) for
2 hr, or LDN193189 (ALK2 and ALK3 inhibitor; Stemgent, San Diego, CA,
USA) for 24 hr before rhSTIP1 was added.
DNA Transfection and Luciferase Reporter Assays
Protocols for DNA transfection and luciferase reporter assays were previously
reported (Wang et al., 2010). Briefly, cells were trypsined and resuspended in
serum-free RPMI at the concentration of 107 cells/ml. A total of 200 ml of cell
suspensions was mixed with 5 mg of reporter DNA and 20 ng of renilla plasmid,
transferred to 2mm gap electroporation cuvette, and pulsed at 120V for 70 ms
with BTX ECM2001 (BTX, Canada). Cells were reseeded into 6-well plates and
cultured in DMEM/F12 with 0.2% fetal bovine serum overnight. During the next
day, cells were treated with rhSTIP1 for 24 hr, and luciferase activity was
measured with the Dual-Luciferase Reporter Assay System (Promega,
Madison, WI, USA) according to the manufacturer’s instructions. Four ID3
promoter reporters, the full-length ID3 promoter construct (nt 4,432 to +75)
and three truncated constructs (2,281 to +75, 982 to +75, and 4,432
to 2,281) (Figure 1C), were kind gifts from Dr. Trevor G. Shepherd of
Dalhousie University, Canada (Shepherd et al., 2008).
Transfection of siRNA
MDAH2774 (3 3 105 cells in 6-well plates) was transfected with 50 nM of
double-stranded RNA in Lipofectamine RNAimax (Invitrogen, Carlsbad, CA,
USA) according to manufacturer’s protocol. Small interfering prions, si-ALK2
and si-ALK3, were purchased fromDharmacon (Lafayette, CO, USA). si-STIP1
was purchased from Sigma-Aldrich; si-Smad1 and si-Smad5 were from
Invitrogen. After 72 hr of transfection, suppression of targeted genes was
confirmed by real-time QPCR and western blot analyses.
Western Blot Analysis
Cell lysates were prepared with RIPA buffer (150 mM NaCl, 20 mM Tris-Cl
[pH 7.5], 1%Triton X-100, 1%NP-40, 0.1%SDS, 0.5%deoxycholate) contain-
ing freshly added proteinase and phosphatase inhibitors (Bionovas, Toronto).
Protein concentrations were assayed with the Bradford method. A total
of 50 mg of each sample was electrophoresed in 10% SDS-PAGE and
transferred to nitrocellulose membranes. All antibodies were from commercial
sources: SMAD1, SMAD4, and SMAD5 (Epitomics, Burlingame, CA, USA);
phospho-SMAD1/SMAD5 (Millipore, Billerica, MA, USA); prion, ID3 (Abcam,
Cambridge); actin (Sigma-Aldrich); and corresponding horseradish peroxi-
dase-conjugated antibodies (Santa Cruz Biotechnology, Santa Cruz, CA,
USA). Enhanced chemiluminescence reagents were from Millipore. The signal
intensity of autoradiogram was quantified using the UN-SCAN-IT software
(Silk Scientific, Orem, UT, USA), and relative intensity of each sample was
normalized by the corresponding actin intensity. For antibody neutralization




















Figure 6. STIP1 Promoted Cell Proliferation through the ALK2-SMAD Signaling Pathway as Shown in Elevated Serum STIP1
(A) The serum levels of STIP1 in patients with ovarian cancer were significantly decreased after surgery (n = 32; p = 0.0049, paired Student’s t test).
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with rhSTIP1 in the presence or absence of anti-STIP1 monoclonal antibody
(Abnova, Taipei, Taiwan) or ALK2-Fc (R&D Systems, Minneapolis) mixtures,
which were preincubated at 37C for 1 hr for 24 hr. Endogenous phospho-
SMAD1/SMAD5 were detected by western blot analysis.
RNA Extraction, Microarray Analysis, and Real-Time QPCR
Total RNA was isolated with TRIzol reagent (Invitrogen). Gene expression
profiles of the STIP1-treated cells and vehicle-treated control cells were
analyzed with a U133A gene chip (Affymetrix, Santa Clara, CA, USA), as
previously reported (Tsai et al., 2007). For real-time QPCR, first-strand cDNA
was synthesized with an oligo-T primer using SuperScript III First-Strand
Synthesis Kit (Invitrogen). Gene expression of ID1, ID3, and GAPDH mRNA
was analyzed with the TaqMan Gene Expression Assay (Applied Biosystems,
Foster City, CA, USA).
ChIP Assay
Briefly, rhSTIP1-treated or control cells were treated with a final concentration
of 1% formaldehyde at RT for 10min to crosslink proteins to DNA. The reaction
was stopped by the addition of glycine (final concentration of 0.125 M). Cells
were scraped from the culture dishes into PBS that contained proteinase
inhibitors. Cell pellets were resuspended in lysis buffer (5 mM PIPES/KOH
[pH 8.0], 85 mM KCL, 0.5% NP-40) and left on ice for 10 min. Nuclei collected
by centrifugation were lysed in nuclear lysis buffer (50 mM Tris [pH 8.1], 10 mM
EDTA, 1% SDS) and incubated on ice for 10 min. Lysates were sonicated to
obtain chromatin with an average length of 600 bp. After centrifugation,
1 mg of protein supernatant was diluted 5-fold in ChIP dilution buffer (0.01%
SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris [pH 8.1], 167 mM
NaCl). Immunocomplexes were precipitated overnight at 4C with 5 mg of
specific antibodies, followed by five sequential washes with low-salt, high-
salt, LiCl, and Tris-EDTA buffer (pH 7.8), respectively (Weinmann et al.,
2001). Washed immunoprecipitates were eluted with elution buffer (1% SDS,
0.1MNaHCO3) at RT, followed by two runs of 15min vortex and centrifugation.
Formaldehyde crosslinks were reversed by incubation in a 65C water bath
for 5 hr. After treatment with Proteinase K followed by phenol/chloroform
extraction, DNA fragments were recovered by ethanol precipitation. Immuno-
precipitated DNA was amplified by real-time QPCR. The primers used to
detect the ID3 enhancer sequence were designed according to a previous
report by Shepherd et al. (2008). The following real-time QPCR conditions
were used: 95C for 10 min, 40 cycles of 95C for 10 s, 60C for 15 s, and
72C for 10 s. The SMAD1/SMAD5 antibodies were purchased from Santa
Cruz Biotechnology.
Immunohistochemistry
Paraffin-embedded ovarian cancer tissues were sectioned to 4 mm, deparaffi-
nized with xylene, and rehydrated with a series of ethanol solutions. Sections
were stained with mouse IgG control, anti-human STIP1 antibody (Abnova),
anti-phospho-SMAD1/SMAD5 antibody (Millipore), anti-ALK2 antibody (Santa
Cruz Biotechnology), or anti-ID3 antibody (Abcam) in an automated immuno-
histochemistry (IHC) stainer with Ventana Basic DAB (3,30-diaminobenzidine)
Detection Kit (Tucson, AZ, USA), according to the manufacturer’s protocol.
Hematoxylin was used for counterstaining. To quantify immunointensity of
each IHC slide, histoscores were calculated by multiplying percentage (%)
of tumor cells (0%–100%) by immunointensities (0–3), as previously described
(Chao et al., 2012).
Ki67 Immunocytochemistry and BrdU Proliferation Assay
Procedures for Ki67 staining and BrdU assay were previously reported
(Wang et al., 2010). For BrdU assays, ovarian cancer cells were seeded at
a density of 104 cells/well in a 96-well plate overnight. After culturing in(B) Colocalization among STIP1, ALK2, phospho-SMAD1/SMAD5, and ID3 in ov
for the first antibody, and the tissues were counterstained by hematoxylin. Scale
lower panels.
(C) Our working model of activation of the ALK2-SMAD-ID3 pathway by secrete
See also Figure S4.serum-free medium for 24 hr, cells were treated with 0.4 mM of rhSTIP1 in
the presence of BrdU for 24 hr. DNA synthesis activity was assayed using
BrdU ELISA kit (Roche Applied Science). For immunocytochemistry studies
of Ki-67, MDAH2774 cells were cultured on Lab-Tek II chamber slides (Nalge
Nunc, Denmark) overnight. After serum starvation or RNAi transfected for
72 hr, cells were treated with 0.4 mM of STIP1 with/without 5 nM of a BMP
inhibitor, LDN193189, or an ERK inhibitor, PD98059, for another 24 hr. The
slides were fixed with 99.9% ethanol, rehydrated with PBS, treated with 3%
hydrogen peroxide for 20 min, permeabilized with 0.1% Triton X-100
(Sigma-Aldrich) for 15min, and stained with anti-Ki67 antibody (Thermo Scien-
tific, Rockford, IL, USA).
Immunofluorescent Microscopy
Cells were cultured on cover slides at the concentration of 33 105 cells/well in
6-well plates overnight, and underwent serum starvation for another 24 hr.
After incubating with 0.4 mM of rhSTIP1 for 15 min at 37C, cells were fixed
with 2% paraformaldehyde at 4C for 30 min, and incubated in blocking buffer
(5% normal goat serum in PBS) to reduce nonspecific binding for 1 hr at RT.
For rhSTIP1 and ALK2 staining, cells were incubated with amousemonoclonal
anti-V5 antibody (Invitrogen; 1:100) to detect the V5 and His-fused rhSTIP1
and a rabbit polyclonal anti-ALK2 antibody (Santa Cruz Biotechnology;
1:100), anti-clathrin antibody (Abcam). After incubation with anti-Alexa Fluor
488 (1:100) and anti-mouse Alexa Fluor 546 (1:100; Invitrogen), the slides
were mounted with VECTASHIELD mounting medium (Vector Laboratories,
Burlingame, CA, USA), and analyzed under the Leica TCS SP2 laser-scanning
confocal system (Leica, Germany).
Immunoprecipitation
After serum starvation for 24 hr, MDAH2774 cells were incubated with 0.4 mM
of rhSTIP1 for 4 hr at 4C. Proteins were crosslinked using 1 mM of Disuccini-
midyl suberate and Bis(sulfosuccinimidyl)suberate (BS3) (Thermo Scientific) at
4 for 30 min as previously reported by Greenwald et al. (2003). Cell lysates
were preparedwith RIPA buffer with proteinase inhibitors, and 2mg of proteins
was incubated with nickel agarose (Invitrogen) at 4C overnight with agitation.
The rhSTIP1 was tagged with V5 and 63 histidine; thus, it adheres to nickel
agarose beads. The nickel agarose was washed three times with native
wash buffer (50 mM NaH2PO4, 500 mM NaCl, 20 mM imidazole [pH 8.0]),
and proteins were eluted from the protein complex by native elution buffer
(50 mM NaH2PO4, 500 mM NaCl, 250 mM imidazole [pH 8.0]). For reversed
immunoprecipitation, ALK2 was immunoprecipitated from 2 mg of protein
extract by using 2 mg of anti-ALK2 antibody (Santa Cruz Biotechnology),
then was performed by ImmunoCruz IP/WB optima system (Santa Cruz
Biotechnology). Each sample was electrophoresed with 8% SDS-PAGE. The
antibody for ALK2 (Santa Cruz Biotechnology) and the antibody for STIP1
(Abnova) or HIS (Millipore) were used for western blot analysis.
ELISA for STIP1
The development of STIP1 ELISA was reported previously (Wang et al., 2010).
Briefly, we used a mouse monoclonal antibody (Abnova) as the capture
antibody, which was coated onto 96-well plates (Nunc F8 MaxiSorp, A/S,
Roskilde, Denmark). Another biotinylated mouse monoclonal antibody
(Abnova) was used as the detection antibody, which could be detected by
the Amdex streptavidin-peroxidase conjugate. TMB substrate was used for
color formation. The reaction was stopped by the addition of 100 ml/well of
1 N H 2SO4. Absorbance was determined at 450 nm in a microplate spectro-
photometer (Molecular Device SPECTRA Max model 190). The detection
sensitivity of our STIP1 ELISAwas 2 ng/ml. Intra-assay CVs of the STIP1 ELISA
were 4.6% at 59.5 ng/ml (n = 6) and 5.6% at 16.5 ng/ml (n = 6). Interassay CVs
were 10.6% at 59.5 ng/ml concentration (n = 7) and 9.4% at 16.5 ng/ml (n = 7).arian cancer tissues was shown by IHC. IgG was used as a negative control
bars represent 100 mm in the upper panels of micrographs and 20 mm in the
d STIP1.
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